I consider myself really privileged. As Director of Research and Policy, I get to attend scientific conferences and report out on the latest research into the early detection and treatment of lung cancer. You may have seen several of my blogs about conferences I have attended. While all of the conferences are interesting, the annual American Association for Cancer Research conference has a special place in my heart.
Being the nerd that I am, I love hearing about advances in pre-clinical research. Scientific conferences focus on different aspects. The annual ASCO meeting, for example...
Lecia Sequist, MD, MPH, the Landry Family Associate Professor of Medicine at Harvard Medical School and a thoracic oncologist at the Massachusetts General Hospital Cancer Center as well as a member of the LUNGevity Scientific Advisory Board, is an expert in targeted therapies for lung cancer. Targeted therapies, or drugs that are designed to attack cancer based on the mutations driving cancer growth, are an important treatment option for many lung cancer patients. I recently spoke with Dr. Sequist about the past, the present, and the future of targeted therapies.
We’ve all read about clinical trials that have been declared successful or unsuccessful. Have you ever wondered who helps make that determination?
I recently spoke with biostatistician Suzanne Dahlberg, PhD, Senior Research Scientist at Dana-Farber Cancer Institute and the Harvard T.H. Chan School of Public Health, and a member of our Scientific Advisory Board. Biostatisticians are key contributors to scientific progress; through the rigorous use of statistics, they ensure that research studies are set up, conducted, and interpreted accurately. Dr. Dahlberg discussed her approach to...
Based on what I learned at the 17th Annual Targeted Therapies of the Treatment of Lung Cancer conference in February in Santa Monica, California, 2017 is going to be an important year for progress in targeted therapies. The conference brings together doctors and scientists from all over the globe to discuss the advances that will result in the best care for lung cancer patients.
As usual, LUNGevity was well represented: 12 members of our Scientific Advisory Board and 15 past and current awardees presented and discussed latest research findings at the conference.